Updated on 16 May 2012
NCKU, Novo Nordisk sign agreement for anti-IL20 antibody
Singapore: A southern Taiwan-based National Cheng Kung University (NCKU) research team led by Ming-Shi Chang, NCKU professor of the epartment of Biochemistry and Molecular Biology, have come up with a potential new anti-osteoporosis and anti-rheumatoid arthritis drug. NCKU, which discovered the anti-interleukin-20 (anti-IL-20) antibody, agreed to license selected intellectual property and transfer certain technology to Novo Nordisk A/S, for a total payment of $13.3 million in case of a successful completion of the project.
In addition, professor Chang and Novo Nordisk A/S have established a two year research collaboration to further strengthen and possible expand the usages of an IL-20 antibody.
Mr Hwung-Hweng Hwung, president, NCKU hailed the groundbreaking discovery of anti-interleukin-20 antibody, "The findings not only mark a milestone in global healthcare, but also raise the visibility of Taiwan's academic research."
This medical discovery was published in the Journal of Experimental Medicine (JEM) and has drawn huge attention in the academic world and the biotechnology industry as well. IL-20 has a key role in osteoclast differentiation, and blockading this cytokine could represent a novel therapeutic approach for osteoporosis, according to data from the NCKU medical team.
The chief editor of Nature Reviews wrote a research highlight in the September issue of Nature Reviews Rheumatology commenting on this finding, while Science-Business eXchange (SciBX) published a cover story reporting on the discovery in the same month. The study not only signifies groundbreaking findings in the pathogenesis of osteoporosis, but could lead to the innovation of new drugs to treat osteoporosis and rheumatoid arthritis.
Professor Chang pointed out that the medical expense of anti-osteoporosis drugs for patients around the world is estimated to be as much as $8 billion per year, and that the amount spent on them by 2015 will be about $8.8 billion. Chang's team has discovered that IL-20 is an important factor in bone cell differentiation and that high serum IL-20 levels in osteoporosis patients cause bone destruction.